Capacity.
Capability.
Promise.
The biggest talent transition of a career. Compete on capacity, not headcount.
This briefing tells you what the talent transition looks like in biotech and research as AI rewrites the firm-worker promise. Read it before someone else writes it for you.
The 10-page briefing. Worth 20 minutes.
One email. One PDF. Worth twenty minutes of your week.
We send it once. Work emails only.
Every CHRO at a mid-sized European specialty biotech has had the same Tuesday, 8:42 a.m. Three things in the inbox. Your Head of Talent forwarded Friday's resignation from your senior regulatory affairs lead, the one who carried the lead programme's IND narrative for four years and is named in the partnership-diligence pack. She went to an AI-native discovery firm. Your CFO attached the Mercer engagement report to the GMT calendar invite. Your CEO forwarded a question from the chair: "the diligence pack flagged key-person dependency on three programmes. Where are we on succession?"
You do not have a retention problem. You have a pathway problem. Your firm's workforce-architecture is being written every week in decisions you were not invited to. The question is not whether to have one. It is whose handwriting the one you already have is in.
Your workforce-architecture is being written every week in decisions you were not invited to. Your senior regulatory leads read the handwriting last month.
This is the question your CEO is already asking. The briefing below is what you want in your hand before the next GMT.
Talent Gravity. Capability Compounding. Succession Readiness.
Three questions every biotech CHRO is tracking. None of them used to be the same question. They are now.
Are your senior specialists staying because of you, or despite you?
Your senior regulatory lead resigned on Friday to an AI-native discovery firm. Your best CMC architect lateral last quarter came from the same place. Senior specialists watch which way you lean the first time something goes wrong. The ones who start looking quietly have already decided.
Is your median senior associate sharper in December than in January?
The top decile is using AI daily on eCTD drafting and regulatory precedent search and building judgement that compounds weekly. The rest is practicing not-knowing. Your L&D budget funds compliance modules and a scientific conference. Neither moves the median.
Of your 2030 senior bench, how many came through work that still exists?
At least three of the six names came through the analyst-prep and submission-drafting work that agents have already absorbed. The external senior hire in 2030 costs a thirty to forty percent premium and brings the previous firm's regulatory-and-CMC context.
What you get when you download
An 11-page report for Chief Human Resources Officers at mid-market European specialty biotech, CDMO, and diagnostic services firms. Designed to be read in one sitting before your next GMT.
Your industry, your people function, and why they are one problem
The senior-specialist bench repricing across specialty biotech, CDMO, and diagnostic services. The junior pathway compressing quietly through 2024 and 2025 as agents absorb analyst-prep and submission-drafting. AI-native discovery firms recruiting your senior regulatory leads. The intersection most CHROs have not named yet: you do not have two problems, you have one.
Four moves across talent, L&D, succession, and trust
Publish the workforce-architecture answer the CEO co-signs in your first 100 days. Ship one senior regulatory role redesigned as a triad unit on a real IND or CTA package. Assemble six senior specialists as the authoring council before any firm-wide redesign. Publish three rules, one escalation, one red line for what the workforce can do with AI.
Five questions for your next GMT
What your three best senior specialists would say privately about whether the firm's AI strategy is being done for them or to them. The role redesigned at task level in the last twelve months. The 2030 senior-specialist bench and which pathways still exist. The deployment fragments you authored versus the ones you decoded after. The senior leads asked to author.
Calibrated for each seat at the table.